UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Details
Datensatz exportieren als...
BibTeX
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
Cancer discovery, 2016-09, Vol.6 (9), p.1006-1021
Zhang, Haikuo
Qi, Jun
Reyes, Jaime M
Li, Lewyn
Rao, Prakash K
Li, Fugen
Lin, Charles Y
Perry, Jennifer A
Lawlor, Matthew A
Federation, Alexander
De Raedt, Thomas
Li, Yvonne Y
Liu, Yan
Duarte, Melissa A
Zhang, Yanxi
Herter-Sprie, Grit S
Kikuchi, Eiki
Carretero, Julian
Perou, Charles M
Reibel, Jacob B
Paulk, Joshiawa
Bronson, Roderick T
Watanabe, Hideo
Brainson, Christine Fillmore
Kim, Carla F
Hammerman, Peter S
Brown, Myles
Cichowski, Karen
Long, Henry
Bradner, James E
Wong, Kwok-Kin
2016
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Zhang, Haikuo
Qi, Jun
Reyes, Jaime M
Li, Lewyn
Rao, Prakash K
Li, Fugen
Lin, Charles Y
Perry, Jennifer A
Lawlor, Matthew A
Federation, Alexander
De Raedt, Thomas
Li, Yvonne Y
Liu, Yan
Duarte, Melissa A
Zhang, Yanxi
Herter-Sprie, Grit S
Kikuchi, Eiki
Carretero, Julian
Perou, Charles M
Reibel, Jacob B
Paulk, Joshiawa
Bronson, Roderick T
Watanabe, Hideo
Brainson, Christine Fillmore
Kim, Carla F
Hammerman, Peter S
Brown, Myles
Cichowski, Karen
Long, Henry
Bradner, James E
Wong, Kwok-Kin
Titel
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
Ist Teil von
Cancer discovery, 2016-09, Vol.6 (9), p.1006-1021
Ort / Verlag
United States
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation. As such, tumors feature a transcriptional program distinct from KRAS- and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting high EZH2 expression. To target EZH2-dependent cancers, we developed a potent open-source EZH2 inhibitor, JQEZ5, that promoted the regression of EZH2-driven tumors in vivo, confirming oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic therapy in a subset of lung cancer. EZH2 overexpression induces murine lung cancers that are similar to human NSCLC with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating biomarkers for EZH2 inhibitor sensitivity. Our EZH2 inhibitor, JQEZ5, promotes regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung cancer. Cancer Discov; 6(9); 1006-21. ©2016 AACR.See related commentary by Frankel et al., p. 949This article is highlighted in the In This Issue feature, p. 932.
Sprache
Englisch
Identifikatoren
ISSN: 2159-8274
eISSN: 2159-8290
DOI: 10.1158/2159-8290.cd-16-0164
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5010480
Format
–
Schlagworte
Animals
,
Antineoplastic Agents - chemistry
,
Antineoplastic Agents - pharmacology
,
Cell Line, Tumor
,
Cell Transformation, Neoplastic - genetics
,
Cell Transformation, Neoplastic - metabolism
,
Chromatin - genetics
,
Chromatin - metabolism
,
Disease Models, Animal
,
Drug Design
,
Enhancer Elements, Genetic
,
Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors
,
Enhancer of Zeste Homolog 2 Protein - genetics
,
Enhancer of Zeste Homolog 2 Protein - metabolism
,
Gene Expression
,
Gene Expression Profiling
,
Gene Expression Regulation, Neoplastic - drug effects
,
Humans
,
Lung Neoplasms - diagnosis
,
Lung Neoplasms - drug therapy
,
Lung Neoplasms - genetics
,
Lung Neoplasms - metabolism
,
Magnetic Resonance Imaging
,
Mice
,
Models, Molecular
,
Molecular Conformation
,
Molecular Targeted Therapy
,
Promoter Regions, Genetic
,
Structure-Activity Relationship
,
Xenograft Model Antitumor Assays
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX